Related Experiment Videos
Practitioners' practical model for managing cancer-related anemia
Robert E Smith1, Simon Tchekmedyian
1South Carolina Oncology Associates, Columbia 29201, USA. RSMITH@SCOncology.net
Oncology (Williston Park, N.Y.)
|October 17, 2002
Summary
Cancer-related anemia causes significant symptoms and impacts quality of life. Early diagnosis and treatment with agents like darbepoetin alfa can improve outcomes and patient well-being.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Anemia is a frequent complication in cancer patients, leading to adverse symptoms and reduced quality of life.
- It can negatively impact disease and treatment outcomes, necessitating a systematic management approach.
Purpose of the Study:
- To highlight the importance of diagnosing and treating cancer-related anemia.
- To discuss erythropoiesis-stimulating proteins (ESPs) as an alternative to blood transfusions.
- To review the efficacy of darbepoetin alfa in anemic cancer patients.
Main Methods:
- Review of current literature on cancer-related anemia.
- Analysis of data regarding ESPs, specifically darbepoetin alfa.
- Evaluation of treatment effects on hemoglobin levels and quality of life.
Main Results:
- Erythropoiesis-stimulating proteins improve quality of life and may enhance cancer treatment outcomes.
- Darbepoetin alfa effectively raises hemoglobin levels and improves quality of life in anemic cancer patients not undergoing chemotherapy or radiotherapy.
- Anemia symptoms are often detected at hemoglobin levels below 12 g/dL.
Conclusions:
- A systematic approach to diagnosing and treating cancer-related anemia is crucial.
- ESPs offer a valuable therapeutic option, improving patient well-being and potentially treatment efficacy.
- Proactive early treatment or prevention of anemia can significantly benefit cancer patients.